Losartan and Emotional Processing in Young People

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Emotional Processing

In brief

This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in young healthy volunteers.

Key facts

Study ID

NCT06636812

Run by

University of Oxford

People needed

60

Starts

2024-03-07

Expected to finish

2025-12-31

Last updated by the study team

2025-06-15

Who can join

Age: 16 and older, up to 20. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Willing and able to provide informed consent (for 16 and 17 year olds: assent and parental/ legal guardian consent)
• Non- or light-smoker (\< 5 cigarettes a day)
• Ability to attend appointments in Oxford with reasonable travel costs
• Ability/ willingness to provide GP contact details

You may not qualify if…

• Past or present DSM-5 axis-I diagnosis (based on SCID results at screening), especially severe psychiatric illness or alcohol or substance dependence
• First-degree family member with severe psychiatric illness
• CNS-medication last 6 weeks (including as part of another study)
• Current blood pressure or other heart medication (especially aliskiren or beta blockers)
• Diagnosis of intravascular fluid depletion or dehydration
• Impaired kidney function (based on blood test at screening, cut-off 75 ml/min/1.73 m2)
• Significant hyperkalaemia (level\>=6mEq/L in the absence of sample haemolysis will be considered significant hyperkalaemia)
• Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/50 mmHg (in accordance with established standard definitions: DOI 10.1186/s12887-016-0633-7))
• Body weight below 35kg (as the lower dose of 25mg of losartan only indicated from 35kg)
• Lifetime history of epilepsy or other neurological disease (e.g. ADHD, autism)
• Lifetime history of angioedema, renal artery stenosis, valvular heart disease, recurrent postural/ orthostatic hypotension
• Lifetime history ofsystemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• Significant loss of hearing that is not corrected with a hearing device Insufficient written and/or spoken English skills
• Women: pregnancy, breast-feeding

Where it is running

• Warneford Hospital, University of Oxford — Oxford, Oxfordshire, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.